Zymeworks Inc (ZYME) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Zymeworks Inc (ZYME) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH186157D
  • |
  • Pages: 57
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Zymeworks Inc (Zymeworks) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody and protein medicines for the treatment of cancer, autoimmune and inflammatory diseases. Its pipeline products include ZW25 and ZW49, novel bispecific antibodies used for the removal of HER2 protein from the cell surface in patients with gastric, breast, and ovarian cancers. Zymeworks' proprietary therapeutic platforms and its fully-integrated drug development engine ZymeCAD, provide the compatibility to engineer and develop highly-differentiated protein-based drugs candidates.The company is developing a pipeline of preclinical product candidates and discovery-stage programs in immuno-oncology and other therapeutic areas. The company has operations in Canada and the US. Zymeworks is headquartered in Vancouver, British Columbia, Canada.

Zymeworks Inc (ZYME)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Zymeworks Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Zymeworks Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Zymeworks Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Zymeworks Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Zymeworks Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Zymeworks Inc, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

Zymeworks Raises USD61.5 Million in Series A Financing 12

Zymeworks Secures USD23.98 Million in Venture Funding 14

Zymeworks Raises USD4 Million in Venture Financing 15

Zymeworks Raises USUSD11 Million In Venture Financing 16

Partnerships 17

ImClone Systems Enters Licensing Agreement with Zymeworks 17

Zymeworks Enters into Research Agreement with University of Victoria and BC Cancer Agency 18

Applied BioMath Extends Partnership with Zymeworks 19

Zymeworks Enters into Agreement with Kairos Therapeutics 20

ProBioGen Enters into Agreement with Zymeworks 21

Zymeworks Enters into Research Agreement with University of California, Los Angeles 22

National Research Council Enters into Co-Development Agreement with Zymeworks for Cancer 23

Licensing Agreements 24

Daiichi Sankyo Enters into Licensing Agreement with Zymeworks 24

Janssen Biotech Enters into Licensing Agreement with Zymeworks 25

Daiichi Sankyo Enters into Licensing Agreement with Zymeworks 26

Zymeworks Enters into Licensing Agreement with Daiichi Sankyo 27

Zymeworks Enters into Licensing Agreement with Innovative Targeting Solutions 28

Zymeworks Enters into Licensing Agreement with GlaxoSmithKline 29

Zymeworks Enters into Licensing Agreement with GlaxoSmithKline 30

Zymeworks Enters into Licensing Agreement with Selexis 31

Celgene Exercises Licensing Agreement with Zymeworks for Bi-Specific Antibody 32

Zymeworks Extends Licensing Agreement with Merck 33

Zymeworks Expands Licensing Agreement with Eli Lilly 34

Zymeworks Enters into Licensing with agreement with Lilly 35

Equity Offering 36

Zymeworks Raises USD85 Million in Public Offering of Share 36

Zymeworks Announces Underwriters Exercise of Over-Allotment Option in IPO 38

Zymeworks Raises USD1.8 Million in Private Placement of Shares 40

Zymeworks Raises USD8.6 Million in Private Placement of Shares 41

Zymeworks Completes Private Placement of Shares for USD17.3 Million 42

Acquisition 43

Zymeworks Acquires Remaining 80.01% Stake in Kairos Therapeutics for USD24.8 Million 43

Zymeworks Acquires 19.99% Stake in Kairos Therapeutics for USD3.6 Million 44

Zymeworks Inc-Key Competitors 45

Zymeworks Inc-Key Employees 46

Zymeworks Inc-Locations And Subsidiaries 47

Head Office 47

Other Locations & Subsidiaries 47

Recent Developments 48

Financial Announcements 48

May 01, 2018: Zymeworks Reports 2018 First Quarter Financial Results 48

Mar 14, 2018: Zymeworks Reports 2017 Year-End Financial Results 50

Nov 08, 2017: Zymeworks Reports Third Quarter 2017 Financial Results and Provides Business Update 51

Aug 08, 2017: Zymeworks Reports Second Quarter 2017 Financial Results 52

May 15, 2017: Zymeworks Reports First Quarter 2017 Financial Results 53

Corporate Communications 54

Feb 14, 2017: Zymeworks Appoints Dr. Kenneth Hillan and Hollings Renton to its Board of Directors 54

Product News 55

Jan 05, 2017: Zymeworks Announces the Successful Achievement of a Research Milestone with Lilly in Bispecific Antibody Collaboration 55

Clinical Trials 56

Mar 14, 2018: Zymeworks Advances Clinical Candidate Incorporating Technology from Kairos Acquisition 56

Appendix 57

Methodology 57

About GlobalData 57

Contact Us 57

Disclaimer 57

List of Figures

Zymeworks Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Zymeworks Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Zymeworks Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Zymeworks Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Zymeworks Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Zymeworks Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Zymeworks Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Zymeworks Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

List of Tables

Zymeworks Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Zymeworks Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Zymeworks Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Zymeworks Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Zymeworks Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Zymeworks Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Zymeworks Raises USD61.5 Million in Series A Financing 12

Zymeworks Secures USD23.98 Million in Venture Funding 14

Zymeworks Raises USD4 Million in Venture Financing 15

Zymeworks Raises USUSD11 Million In Venture Financing 16

ImClone Systems Enters Licensing Agreement with Zymeworks 17

Zymeworks Enters into Research Agreement with University of Victoria and BC Cancer Agency 18

Applied BioMath Extends Partnership with Zymeworks 19

Zymeworks Enters into Agreement with Kairos Therapeutics 20

ProBioGen Enters into Agreement with Zymeworks 21

Zymeworks Enters into Research Agreement with University of California, Los Angeles 22

National Research Council Enters into Co-Development Agreement with Zymeworks for Cancer 23

Daiichi Sankyo Enters into Licensing Agreement with Zymeworks 24

Janssen Biotech Enters into Licensing Agreement with Zymeworks 25

Daiichi Sankyo Enters into Licensing Agreement with Zymeworks 26

Zymeworks Enters into Licensing Agreement with Daiichi Sankyo 27

Zymeworks Enters into Licensing Agreement with Innovative Targeting Solutions 28

Zymeworks Enters into Licensing Agreement with GlaxoSmithKline 29

Zymeworks Enters into Licensing Agreement with GlaxoSmithKline 30

Zymeworks Enters into Licensing Agreement with Selexis 31

Celgene Exercises Licensing Agreement with Zymeworks for Bi-Specific Antibody 32

Zymeworks Extends Licensing Agreement with Merck 33

Zymeworks Expands Licensing Agreement with Eli Lilly 34

Zymeworks Enters into Licensing with agreement with Lilly 35

Zymeworks Raises USD85 Million in Public Offering of Share 36

Zymeworks Announces Underwriters Exercise of Over-Allotment Option in IPO 38

Zymeworks Raises USD1.8 Million in Private Placement of Shares 40

Zymeworks Raises USD8.6 Million in Private Placement of Shares 41

Zymeworks Completes Private Placement of Shares for USD17.3 Million 42

Zymeworks Acquires Remaining 80.01% Stake in Kairos Therapeutics for USD24.8 Million 43

Zymeworks Acquires 19.99% Stake in Kairos Therapeutics for USD3.6 Million 44

Zymeworks Inc, Key Competitors 45

Zymeworks Inc, Key Employees 46

Zymeworks Inc, Subsidiaries 47

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Zymeworks Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16863
Site License
USD 500 INR 33725
Corporate User License
USD 750 INR 50588

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com